These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 28030798)
1. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798 [TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation. Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L Br J Haematol; 2018 Apr; 181(1):129-133. PubMed ID: 28025833 [No Abstract] [Full Text] [Related]
4. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775. Hauge S; Macurek L; Syljuåsen RG Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845 [TBL] [Abstract][Full Text] [Related]
5. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells. Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. Mak JP; Man WY; Ma HT; Poon RY Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733 [TBL] [Abstract][Full Text] [Related]
7. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012 [TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237 [TBL] [Abstract][Full Text] [Related]
9. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408 [TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. Magnussen GI; Emilsen E; Giller Fleten K; Engesæter B; Nähse-Kumpf V; Fjær R; Slipicevic A; Flørenes VA BMC Cancer; 2015 Jun; 15():462. PubMed ID: 26054341 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. Mak JP; Man WY; Chow JP; Ma HT; Poon RY Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928 [TBL] [Abstract][Full Text] [Related]
13. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697 [TBL] [Abstract][Full Text] [Related]
14. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190 [TBL] [Abstract][Full Text] [Related]
15. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
16. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202 [TBL] [Abstract][Full Text] [Related]
17. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911 [TBL] [Abstract][Full Text] [Related]
18. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Aarts M; Bajrami I; Herrera-Abreu MT; Elliott R; Brough R; Ashworth A; Lord CJ; Turner NC Mol Cancer Ther; 2015 Apr; 14(4):865-76. PubMed ID: 25673822 [TBL] [Abstract][Full Text] [Related]
19. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088 [TBL] [Abstract][Full Text] [Related]
20. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Saini P; Li Y; Dobbelstein M Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]